Mechanisms of disease: HDL metabolism as a target for novel therapies.
about
Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out miceDouble Superhelix Model of High Density LipoproteinNovel concepts in HDL pharmacology.Particulate matter and atherosclerosis: role of particle size, composition and oxidative stressAcute-phase-HDL remodeling by heparan sulfate generates a novel lipoprotein with exceptional cholesterol efflux activity from macrophages.Scavenger receptor BI facilitates hepatic very low density lipoprotein production in mice.Congruency between biophysical data from multiple platforms and molecular dynamics simulation of the double-super helix model of nascent high-density lipoprotein.Beneficial effects of Hibiscus rosa-sinensis L. flower aqueous extract in pregnant rats with diabetes.Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery.Proprotein convertases in high-density lipoprotein metabolism.Serum opacity factor enhances HDL-mediated cholesterol efflux, esterification and anti inflammatory effects.Znf202 affects high density lipoprotein cholesterol levels and promotes hepatosteatosis in hyperlipidemic mice.Regulation of ABCA1 functions by signaling pathwaysThe low-resolution structure of nHDL reconstituted with DMPC with and without cholesterol reveals a mechanism for particle expansion.Activation of the liver X receptor stimulates trans-intestinal excretion of plasma cholesterol.Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions.Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndrome.Apolipoprotein D in lipid metabolism and its functional implication in atherosclerosis and aging.Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses.From blood to gut: direct secretion of cholesterol via transintestinal cholesterol efflux.A novel gene regulator, pyrrole-imidazole polyamide targeting ABCA1 gene increases cholesterol efflux from macrophages and plasma HDL concentration.Discovery of substituted biphenyl oxazolidinone inhibitors of cholesteryl ester transfer protein.Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice.Trans-intestinal cholesterol efflux is not mediated through high density lipoprotein.The refined structure of nascent HDL reveals a key functional domain for particle maturation and dysfunction.Niacin increases HDL biogenesis by enhancing DR4-dependent transcription of ABCA1 and lipidation of apolipoprotein A-I in HepG2 cells.Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.Lipid goal achievement and trends in lipid-lowering therapy in veterans undergoing carotid endarterectomy.
P2860
Q24300591-DF722B13-EF76-422F-A0A9-6A99AB8A4378Q27657720-93CF79BC-F2AC-4CAF-BBD6-956F6D4D05D5Q27692691-41442D95-63D3-4112-8BB3-BE7A88E11F1CQ28391543-8F209E7F-E691-43CF-8957-FDDB40A7DFD1Q33389832-2A786DF3-8A91-4C9E-9DD6-C799B5F1D053Q33634141-B6CE6725-2FC6-47FC-8A9C-8D032E8159DDQ33650108-C2DB4512-1F74-4E9A-A9C9-7D2C8D7828F0Q33828860-0A86F951-F434-438B-84E5-E456ECFB2395Q33830955-A6A6EAEE-2E8D-4F9D-A7D6-579FD0F6E8D9Q34256139-73845517-EC00-4B5F-85BD-52DCD14A4F4FQ34562290-94C447E8-C51C-4A56-BE8E-197402DC6FC6Q34612131-039CFEB2-A0AB-4A58-91E6-1F6391C04B8DQ35626943-37ED2D3F-8E57-4302-AD35-A64D88CB162CQ36709650-F42D78F9-E7E4-4DEF-B3E0-25ABEAFDC685Q37339259-EA8C541F-3CB4-469D-9E0B-09BAC5CB3086Q37373876-A8CF0D25-E9CE-491C-BED2-65F8884A32A1Q37434362-BD7683F2-9E29-448C-A9DD-B0211D81EE27Q37444311-14592787-A9FB-4C1B-B3EF-BC51764A4353Q37606964-9E0FA347-E80A-4611-8A5E-B1683CE4367DQ37820951-752901C0-25B4-45C1-9E04-1146AF69E19AQ39030584-A70B7B0F-CB72-4789-9165-57DC17610785Q39514003-131D368D-94E5-4D8C-B0D8-1B7A6FA225AFQ39788178-086F8EB8-E1E0-4760-8FA5-5243636E83E3Q42129050-8EA235DB-D8EE-4727-B881-FD100469E724Q42152420-6ABCEEC2-D64E-4C07-B660-2D75A415ABC1Q42540382-B5E2BB6A-8120-466B-963B-6EF3ED68DBA9Q42562376-B678BCDD-AA4A-41F3-AA39-476DBB219FDBQ45331634-8C13EACD-5CF2-46F8-96B6-5300750C07E9
P2860
Mechanisms of disease: HDL metabolism as a target for novel therapies.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Mechanisms of disease: HDL metabolism as a target for novel therapies.
@ast
Mechanisms of disease: HDL metabolism as a target for novel therapies.
@en
type
label
Mechanisms of disease: HDL metabolism as a target for novel therapies.
@ast
Mechanisms of disease: HDL metabolism as a target for novel therapies.
@en
prefLabel
Mechanisms of disease: HDL metabolism as a target for novel therapies.
@ast
Mechanisms of disease: HDL metabolism as a target for novel therapies.
@en
P356
P1476
Mechanisms of disease: HDL metabolism as a target for novel therapies.
@en
P2093
Daniel J Rader
P304
P356
10.1038/NCPCARDIO0768
P577
2007-02-01T00:00:00Z